back

BioTechSynthesis

View Menu
BioTechSynthesis

BioTechSynthesis

Only together we can improve people's health and make their lives happier.
 

Oncology
BioTechSynthesis

16

AIDS
BioTechSynthesis

16

immunity
BioTechSynthesis

16

diabetes
BioTechSynthesis

16

Heart
BioTechSynthesis

16

Vessels
BioTechSynthesis

16

Antibiotics
BioTechSynthesis

16

Blood
BioTechSynthesis

16

Ulcer
BioTechSynthesis

16

Different
BioTechSynthesis

16

back

Oncology
Medication


1. BORTEZOMIB
Modified boric acid is a highly selective reversible inhibitor of 26S proteasome activity present in the nucleus and cytosol of all eukaryotic cells and catalyzes the splitting of main proteins involved in the life cycle of cells. Himotripsinopodobnye bortezomib inhibits the proteasome, causes inhibition of proteolysis and leads to apoptosis. Myeloma cells (in vitro) to 1000 times more susceptible to apoptosis induced by bortezomib than normal plasma cells. The mechanism of destruction of cells of myeloma is in blockade of activation of NF-kB, which in normal cells NF-kB (exists as a dimer P50-P65) is associated with an inhibitory protein LkB holding it in an inactive form in the cytosol. Some tumors contain the activated forms of NF-kB. The proteasome catalyzes the proteolytic generation of the subgroup of NF-kB P50 from the inactive precursor р150 and destruction of the inhibitory protein LkB. Activated NF-kB, penetrating into the core, affects the survival and proliferation of cells. All this helps to reduce the number antiapoptotic factors, inflammatory molecules, cell adhesion molecules (allow connecting the cells attach to bone marrow cells) and cytokines (which stimulate the growth of myeloma cells). In vivo bortezomib caused a slowdown in the growth of many experimental human tumors, including multiple myeloma.
2. IMATINIB
An antitumor agent, an inhibitor proteincontaining (Bcr-Abl tyrosine kinase) is an abnormal enzyme produced by Philadelphia chromosome in chronic myeloid leukemia. Inhibits the proliferation and induces apoptosis of Bcr-Abl-positive cell lines, as well as young leukemic cells with Philadelphia chromosome-positive chronic myeloid leukemia (CML). In research on the formation of colonies, carried out ex vivo on samples of peripheral blood and bone marrow it was shown that imatinib inhibits Bcr-Abl-positive colonies obtained from patients with chronic myeloid leukemia. The studies in vivo inhibits tumor growth of Bcr-Abl murine myeloid cells subjected to transfection, and Bcr-Abl-positive leukemia lines derived from patients with chronic myeloid leukemia in blast crisis. Imatinib also inhibits the receptor tyrosine kinase platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit (Kit, CD117), and inhibits cellular responses mediated by these factors. In vitro, imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumours expressing c-kit mutations.
3. Rituximab
Rituximab is a chimeric monoclonal antibody mouse/human that specifically binds to the transmembrane antigen CD20. This antigen is located on pre-b lymphocytes and Mature b lymphocytes, but is absent on hematopoietic stem cells, Pro-b cells, normal plasma cells, cells of other tissues and is expressed in more than 95% of cases with b-cell non-Hodgkin lymphomas. After binding to the CD20 antibody does not internalized and ceases to flow from the cell membrane into the extracellular space. CD20 does not circulate in plasma as free antigen and thus does not compete for binding with antibodies.
4. Bevacizumab
Bevacizumab is a recombinant hyperkalemia (humanized, approximate to the human) monoclonal IgG1 antibody that selectively bind and inhibit the biological activity of the growth factor vascular endothelial (VEGF) in vitro and in vivo. Bevacizumab contains human skeleton plots complementarity determining plots hipermercado mouse antibody that binds to VEGF. Binds to VEGF and prevents the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to proliferation of endothelial cells and formation of new blood vessels on the models of angiogenesis in vitro. The introduction of Bevacizumab models xenotransplanted cancer of the rectum in mice with the nu mutation (main mutation of the existence of nu — absence of the thymus and a wool cover) reduces the vascularization and inhibition of tumor growth. Bevacizumab is a recombinant hyperhaline (humanized, approximate to the human) monoclonal antibody that selectively binds to a biologically active VEGF and neutralizes it. Bevacizumab inhibits VEGF with its receptors (Flt-1, KDR) on the surface of endothelial cells, resulting in decreased vascularization and inhibition of tumor growth.Bevacizumab contains the fully human skeleton plots complementarity determining plots hipermercado mouse antibody that binds to VEGF. Receive bevacizumab by recombinant DNA technology in the system for the expression of, submitted by Chinese hamster ovary cell. Bevacizumab consists of 214 amino acids and has a molecular weight of approximately 149000 daltons. The introduction of Bevacizumab leads to the suppression of metastatic progression of the disease and reduce microvascular permeability in various human cancers, including cancer of the colon, breast, pancreas and prostate.
5. Trastuzumab
Trastuzumab inhibits proliferation of human tumor cells c overexpression of HER2. In vitro antibody-dependent cellular cytotoxicity trastuzumab mainly focuses on tumor cells with overexpression of HER2.
6. Temozolomide
Malignant glioma (glioblastoma multiforme, anaplastic astrocytoma) in the presence of relapse or disease progression after standard therapy; metastezirutaya common malignant melanoma (1 line therapy).
7. Pomalidomide
A medicament for the treatment of patients with multiple myeloma who have received at least two cycles of therapy (including the medications lenalidomide and bortezomib), and they proved ineffective and led to the progression of the disease.The effect of the medication (pomalidomide) is based on the stimulation of the immune system to destroy cancer cells and suppress their growth. The safety and efficacy of the medication was evaluated in clinical studies involving patients with relapsing or resistant multiple myeloma. Participants were randomly assigned to receive only medication (pomalidomide) and obtaining medications in combination with low doses of dexamethasone and corticosteroids.The medication is contraindicated in pregnancy because it can provoke threat for life of congenital malformations, as well as taking it promotes the formation of blood clots. The most common side effects associated with the medication, decreased number of red blood cells in the blood, weakness, fatigue, back pain, fever.
8. Panobinostat
Panobinostat experimental medication (panobinostat) increases survival without progression of disease in patients with multiple myeloma. Panobinostat is an oral inhibitor of the enzyme histone deacetylase, blocking of which causes the death of cancer cells.
9. Ixazomib
A fundamentally new medication for the treatment of recurrent and resistant forms of multiple myeloma. An experimental oral medication Exosomes (Ixazomib) is a first-in-class inhibitor of the proteasome which prevents the degradation of regulatory proteins. It reduces the expression of transcriptional nuclear factor NF-kB, which protects tumor cells from death due to apoptosis.
10. Elotuzumab
The medication elotuzumab experimental monoclonal antibody designed for the treatment of multiple myeloma. The safety profile of the medication elotuzumab can be considered constant. Side effects associated with the use of the medication occurred within 18 months from the start of treatment. Most of these were thrombocytopenia, neutropenia, of cardiovascular system the lymphocytopenia, Hyper - and hypokalemia, diarrhea, fatigue, pneumonia. However, the study has recorded two fatalities with multiple side effects, including sepsis, pneumonia and multiple organ failure.
11. Venetoclax
Fundamentally new medication experimental medication Venetoklis (venetoclax). The medication is intended for treatment of recurrent chronic lymphocytic leukemia in patients with the del17p mutation chromosome.Venetoklis the medication is an oral inhibitor of BCL-2 protein, is involved in the apoptosis of cells.
12. Сeritinib
Sericini the medication is intended to treat patients with metastatic non-small cell lung cancer (ALK+). Caritine belongs to the group of inhibitors of ALK. The medication blocks proteins that promote development of cancer cells, and is intended for patients previously treated with christineb.
13. Sorafenib
Antitumor agent directed action. Multikinase is a low molecular weight inhibitor. Provides a reduction in the proliferation of tumor cells in vitro. It has been shown that it inhibits both intracellular kinases (serine/trionychinae c-CRAF, BRAF and mutant BRAF) and located at the cell surface receptor tyrosine kinase. In clinical trials found that sorafenib suppresses tumor growth in renal cell and hepatocellular carcinoma in humans.
14. Lenalidomide
Treatment (in combination with dexamethasone) in patients with multiple myeloma who have received at least one line of therapy.
15. Filgrastim, Neupogen
Use of the substance Filgrastim: neutropenia (including in patients receiving cytotoxic medications about amiloidnykh malignant tumors); reduced the duration of neutropenia and its clinical consequences in patients preparing for bone marrow transplantation; persistent neutropenia in patients with extensive stage AIDS infection (absolute neutrophil count 1000 cells/µl or less); mobilization of peripheral stem cells (including post-myelosuppressive therapy); neutropenia (hereditary, idiopathic or recurrent — the number of neutrophils is below or equal to 500 cells/µl) and severe or recurrent infections (in history) in the last 12 months.
16. Darbepoetin alfa, Aranesp
Treatment of symptomatic anemia in adults and children with chronic renal failure (CRF); treatment is symptomatic anemia in adult cancer patients with amiloidnykh malignancies receiving chemotherapy.
17. Abemaciclib
Is an inhibitor of cyclin-dependent kinase 4/ 6 and is designed to treat patients with refractory hormone receptor-positive (HR+) common or metastatic breast cancer.
18. Olaparib
Is an effective means of therapy of malignant serous and undifferentiated ovarian carcinomas.
19. Rociletinib
Rollatini medication used to treat non-small cell lung cancer in patients with initial active EGFR mutations with a dominant mutation T790M.
20.Necitumumab
Necitumumab is designed to treat non-small cell lung cancer
21. Talimogene laherparepvec
TALMAGE lagerpeton is designed to treat patients with local or widespread metastatic melanoma.
22. Osimertinib
The medication is intended to treat metastatic non-small cell lung cancer in patients with a positive T790M mutation status of the receptor of epidermal growth factor (epidermal growth factor receptor, EGFR), have had a progression of disease during or after therapy with EGFR tyrosine kinase inhibitor.

AIDS
Medication

1. Abacavir
Inhibits reverse transcriptase of AIDS−1 and AIDS−2. Causes chain breakage of RNA and stops replication of the virus. Quickly and adequately absorbed after oral administration. The absolute bioavailability of 83%. Cmax achieved through 1-1. 5 h is about 3 mcg/ml. meal slows down the absorption. In the blood bound to proteins, easily passes gistogematicalkie barriers (except BBB) and penetrates the tissues, volume of distribution is 0.8 l/kg Metabolised in the liver, with the participation of alcohol dehydrogenase and glucuronyltransferase. About 66% of the dose is excreted in the form of glucuronid conjugates (only 2% in unmodified form) mainly by the kidneys (over 80%) and partly with faeces; T1/2 is 1.5 hours Not koumouliruet. In a combination therapy (combination with AZT and Epivir), slows the progression of AIDS infection, reduce the frequency and severity of AIDS-associated diseases, improves immune system function.
2. Kaletra (Lopinavir, Ritonavir,Norvir)
Antiviral agent, a peptide inhibitor of AIDS-1 and AIDS-2 proteases. Enzymatic cleavage of the protease prevents the activation of the protein precursor and leads to the synthesis of immature AIDS particles unable to initiate further development of the infection. Proteolysis of polypeptides of AIDS life cycle stops its replication. Binds C2-symmetric part of the active area of AIDS protease, has a high selective affinity for and has a weak inhibitory effect on the protease of human rights. Increases the number of CD4 cells in the blood and reduces the concentration of viral RNA. Leads to an increase in the total number of white blood cells, lymphocytes and platelets.
3. Darunavir
Darunavir is an inhibitor of dimerisation and the catalytic activity of the protease of human immunodeficiency virus 1 type (AIDS-1). The medication selectively inhibits the cleavage of the polyproteins Gag-Pol AIDS in the virus infected cells, preventing formation of complete viral particles.Darunavir tightly binds to the AIDS-1 protease (KD of 4.5 x 10-12 mol/l). Darunavir-resistant mutations that cause resistance to protease inhibitors. Darunavir does not inhibit any of the 13 studied cellular proteases person.
4. Zidovudine
Embedded in the viral DNA chain and blocks its formation, promoting its breakage. The competition of the medication for AIDS reverse transcriptase is approximately 100 times stronger than alpha-polymerase-cellular DNA of a human.
5. Atazanavir
Azapeptide atazanavir is a protease inhibitor of AIDS-1. This substance selectively inhibits the virus-specific processing of viral Gag-Pol proteins in AIDS-infected cells, preventing formation of Mature virions and infecting other cells. During treatment some patients can develop resistance (resistance) to the medication (specific resistance) or to act as atazanavir and other AIDS protease inhibitors (cross-resistance).
6. Raltegravir
Raltegravir acts on the integrase, the enzyme AIDS, combining viral genetic material in the chromosomes of humans and plays an important role in the pathogenesis of AIDS. The medication is metabolized by glucuronidase.

IMMUNITY

IMMUNOMODULATORY
Medication

1. Glatiramer Acetate
Is the acetate salt of a mixture of synthetic polypeptides formed by 4 natural amino acids: L-glutamic acid, L-alanine, L-tyrosine and L-lysine, and chemical structure has similarities with the basic protein of myelin. Of glatiramer acetate alter the course of pathological process in demyelinizing disease of the Central nervous system — multiple sclerosis which is an autoimmune disease that alters the ratio of T-suppressors in the body.
2. Agomelatine
Agomelatine is an agonist of МТ1 melatoninonline and MT2 receptors and antagonist of serotonin 5-HT2WITH-receptors.Agomelatine is an antidepressant, is active on validated models of depression (acquired helplessness test, despair test, chronic stress moderate symptoms), as well as on models with the desynchronization of circadian rhythms, as well as in experimental situations of anxiety and stress. It was shown that agomelatine does not affect the capture of monoamines and has no affinity for alpha-, beta-adrenergic, histaminergic, cholinergic, dopaminergic and benzodiazepine receptors.
3. (Interferon beta-1a)
The medication has immunomodulatory, antiviral and antiproliferative properties. The protein structure of the medication (interferon beta-1A recombinant human) is a natural amino acid sequence of human interferon beta, obtained by genetic engineering using cell culture Chinese hamster ovary.
4. Fingolimod
Immunosuppressive medication used for treatment of multiple sclerosis. It modulates the receptors of sphingosine-1-phosphate (SlP receptors). Fingolimod is metabolized by sphingosine to the active metabolite of fingolimod phosphate. In low concentrations of mu fingolimod phosphate binds with SlP-receptors of b lymphocytes 1, 3, and 4 types and quickly penetrates the Central nervous system (CNS) through the blood-brain barrier, binding to SlP receptors of nerve cells 1, 3, and 5 types. SlP binding-receptors of lymphocytes, fingolimod phosphate blocks the capacity of lymphocytes to leave lymph nodes, which leads to a redistribution of lymphocytes in the body. It does not reduce the total number of lymphocytes in the body.
5. Dimethyl fumarate
Oral medication for the treatment of multiple sclerosis.
6. Teriflunomide
medication for treatment of multiple sclerosis.

Immunosuppressants

1. Hydroxychloroquine sulfate
Antimalarial, anti-inflammatory agent, an immunosuppressant
2. Etanercept (Enbrel)
The medication, which combines in its structure two proteins that are normally encoded by separate genes: the receptor of tumor necrosis factor (TNF) Fc-plot of human immunoglobulin G1. On the principle of action etanercept is a TNF inhibitor. Etanercept binds to TNF and reduces its role in the development of disorders resulting in abnormal inflammation in humans and animals, including autoimmune diseases (such as ankylosing spondylitis or ankylosing spondylitis, juvenile rheumatoid arthritis (eng.), psoriasis, psoriatic and rheumatoid arthritis), and possibly other diseases associated with excess TNF.
3. Tacrolimus
Prevention and treatment of allograft rejection of bone marrow,liver, kidney and heart, including resistant to standard immunosuppressive therapy regimes. Taking Tacrolimus is an empirical therapy refractory to corticosteroid therapy in cases of autoimmune hepatitis.
4. Infliximab
Selective immunosuppressant. Infliximab is a chimeric compound based on hybrid mouse and human IgG1 monoclonal antibodies. Infliximab has a high affinity to Fnaa, which is a cytokine with broad biological activity, is a mediator of the inflammatory response and is involved in reactions of the immune system. Fnoa plays a role in the development of autoimmune and inflammatory diseases. Infliximab rapidly binds and forms a stable compound with both forms (soluble and transmembrane) human Fnaa,reducing the functional activity of Fnoa.

Diabetes
Medication

1. Trelagliptin
(Diabetes)
2. Alogliptin
Alogliptin is a highly selective inhibitor of DPP-4. In clinical studies of up to two years application alogliptin, both in monotherapy and in combination with other sugar-reducing medications resulted in significant improvement in glycaemic control in patients with type 2 diabetes, including old age. Application alogliptin accompanied by a low risk of hypoglycaemia and lack of weight gain. In patients at very high cardiovascular risk the use of alogliptin-on not associated with an increased risk of cardiovascular events.
3. Lixisenatide
With the introduction of 1 time per day patients with diabetes mellitus type 2 licesence improves glycemic control due to the fast growing since its introduction and sustained reductions in the concentration of glucose in the blood after meals and on an empty stomach.
4. Insulin glargine
Insulin glargine is an analogue of human insulin. Obtained by the method of recombination of DNA of the bacteria species Escherichia coli (K12 strains). It has low solubility in a neutral environment. In the medication Lantus completely soluble, which is an acid environment solution for injection (pH=4). After the introduction in the subcutaneous fat solution due to its acidity reacts with the neutralization of the formation of microprecipitates from which constantly releases small amounts of insulin glargina, ensuring a smooth (without the peaks) profile curve "concentration-time", as well as longer duration of medication action. The parameters bind to insulin receptors of insulin glargine and human insulin are very close. Insulin glargine has biological activity similar to endogenous insulin.

Heart
Medication

1. Candesartan cilexetil
Arterial hypertension; heart failure and impaired systolic function of the left ventricle (as additional therapy to ACE inhibitors or intolerance to ACE inhibitors).
2. Propanolol
Arterial hypertension; stable angina, unstable angina; sinus tachycardia (including in hyperthyroidism), supraventricular tachycardia, tachysystolic form of atrial fibrillation, supraventricular and ventricular premature beats, essential tremor, migraine prophylaxis, alcohol withdrawal (agitation, and tremor), anxiety, pheochromocytoma (adjuvant treatment), diffuse toxic goiter and thyrotoxic crisis (as subsidiary means, including intolerance to thyreostatics medications), sympathoadrenal crises on the background of diencephalic syndrome.

Vessels
Medication

VASOCONSTRICTOR, ANTIKONGESTIVNE
1. Naphazoline
Stimulates alpha1 - and ALPHA2-adrenergic receptors, causes vasoconstriction (primarily affects the vessels with the highest density of alpha-adrenoceptor — vessels of the mucous membranes and kidneys), the pupil narrows, has anti-inflammatory (anti-edema) properties. Vasoconstrictive effect for local application to the mucous membrane of the nose and eyes occurs within minutes and lasts for hours. In rhinitis nasal breathing easier, reducing blood flow to the venous sinuses. Systemic effect manifested by increased blood pressure.
2. Xylometazoline
Stimulates alpha-adrenergic receptors. When a local little absorbed, so the concentration in plasma is very low (not determined analytically). When applied to mucous membranes causes vasoconstriction, reducing local redness and swelling. In rhinitis nasal breathing easier. The action occurs within a few minutes and lasts for hours.
3. Oxymetazolinum
Vasoconstrictor medication for topical application, used as a component of funds from a cold.

Antibiotics
Medication

1. Rifaximin
(Hepatic encephalopathy)
The broad-spectrum antibiotic, is a semisynthetic derivative of rifamycin SV. Inhibits DNA-dependent RNA polymerase of bacterial cells and causes their death. Broad antibacterial spectrum of rifaximin suppresses pathogenic intestinal bacterial flora, which causes a number of pathological conditions. Rifaximin reduces the formation by bacteria of ammonia and other toxic compounds, which in the case of severe liver disease, accompanied by violation of the detoxification process, are involved in the pathogenesis and symptomatology of hepatic encephalopathy. Reduces the increased proliferation of bacteria in the syndrome of excessive growth of microorganisms in the intestines. In the diverticula of the colon reduces the number of bacteria that can participate in inflammation around the diverticular SAC, and may play a key role in the development of symptoms and complications of diverticular disease.
2. Trimethoprim
Bacteriostatic antibiotic mainly used for the prevention and treatment of diseases of the urinary system.

Blood
Medication

Filgrastim (Neupogen)
To reduce the duration of neutropenia and the frequency of febrile neutropenia in patients receiving chemotherapy cytotoxic medications for malignant diseases (except chronic myeloid leukemia and myelodysplastic syndrome), also reducing the duration of neutropenia and its clinical in posledstviyami in patients receiving therapy with myeloablative in posledstviyami bone marrow transplantation. For mobilization of autologous progenitor cells hematopoiesis in the peripheral blood, including in consequence of myelosuppressive therapy to accelerate recovery of hematopoiesis by introduction of these cells in consequence of mielosupression or myeloablative. Long-term therapy to increase the number of neutrophils and reduce the frequency and duration of infectious complications in children and adults with severe congenital, malignant or recurrent neutropenia (absolute neutrophil count <500/µl) and severe or recurrent infections in history.

Antiulcer
Medication

1. Esomeprazole
Esomeprazole is the S-isomer of omeprazole and reduces the secretion of hydrochloric acid in the stomach by specific inhibition of the proton pump in the parietal cells of the stomach. S - and R-isomers of omeprazole have similar pharmacodynamic activity.
2. Dexlansoprazolum
Dexlansoprazole is a proton pump inhibitor, suppresses gastric acid secretion by inhibiting H+/K+-ATPase in the parietal cells of the stomach. Blocking final stage secreting hydrochloric acid.

Different
Medication

Parkinson disease

Rasagiline
Antiparkinsonian agent, a selective irreversible inhibitor of MAO type b, which is 80% determine MAO activity in the brain and metabolism of dopamine. Rasagiline in 30-80 times more active against MAO-b than MAO type A. it Increases the concentration of dopamine, reduces the formation of toxic free radicals, excessive formation of which is observed in Parkinson's disease. Rasagiline has a neuroprotective effect, in therapeutic doses does not block the metabolism from food of biogenic amines (incl. tiramina), and therefore it does not cause tyramine-induced hypertensive syndrome.

Bronchial asthma

1. Fenspiride
The application is rhinopharyngitis, laryngitis, rinotraheobronhit, otitis media, sinusitis, chronic bronchitis with respiratory failure, bronhospasticski syndrome, bronchial asthma (supportive therapy), respiratory dysfunction in measles, whooping cough, influenza.
2. Poractant alfa
Respiratory distress syndrome in premature newborns weighing more than 700 g.

Non-narcotic analgesics

1. Celecoxib
medication, nonsteroidal anti-inflammatory medication from the group of coxibs. Used to treat osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce the number of polyps of the colon and rectum in patients with familial adenomatous polyposis. The representative of the new generation non-steroidal anti-inflammatory medications — selective COX-2 inhibitors. Selectively disrupts the formation of the prostaglandins involved in the formation of inflammatory reaction and does not affect production of prostaglandins that regulate renal blood flow and the integrity of the mucous membranes of the gastro-intestinal tract. Has a pronounced anti-inflammatory and analgesic effect.

Obesity

1. Naltrexone/Bupropion
medication for weight loss complex active substance "bupropion + naltrexone". Contrave is used in the therapy involving reduction of caloric content of food taken by the patient and increase physical activity. Both active substances are psychotropic medications, intended for influence on the Central nervous system to ease the patient's psychological state, moved to another system and changed the way of life.

OPHTHALMOLOGY

1. Taurine
Taufon (taurine) is a sulfur-containing amino acid formed in the body in the process of making zisteina. The medication improves energy metabolism, stimulates reparative processes in degenerative diseases, and contributes to restoration of disturbed metabolism of eye tissues. As sulfur-containing amino acid, the medication normalizes the function of cell membranes, improves metabolic (incl. energy) processes.

Gout

1. Febuxostatum
Treatment of hyperuricemia in chronic gout.
2. Lesinurad (Zurampic)
The medication is intended for treatment of chronic hyperuricemia. In combination with allopurinol (allopurinol are), an inhibitor of xanthine oxidase, or in combination with febuxostat (febuxostat) medication lisinoril can be administered to treat gout. The medication is a selective inhibitor of reabsorbtsii uric acid. The effect of the medication aimed at blocking the uric acid Transporter URAT1, which increases the excretion of uric acid from the body.

Sexual potency

1. Sildenafil citrate
medication for increasing sexual potency.

Antiemetic

1. Ondansetron
Antiemetic medication of Central action, a selective antagonist of serotonin 5NT3 receptors. Mainly used to suppress nausea and vomiting resulting from chemotherapy. It acts both at peripheral and Central nervous system, reducing the activity of the vagus nerve that suppresses the gag reflex, and it also blocks the receptors trigger zone of the brain that triggers this reflex.

Antiepileptic medications

1. Pregabalin
Indications - neuropathic pain in adults; epilepsy (as adjunctive therapy in adults with partial seizures accompanied or not by secondary generalization); generalized anxiety disorder in adults; fibromyalgia in adults.
2. Levetiracetam
Active ingredient levetiracetam is a derivative of piracetam, is not related to existing antiepileptic active components, does not alter normal neurotransmission. The effect of the medication is confirmed in conditions such as focal and epilepsy (epileptiform manifestations / photoparoxysmal reaction).

The Central nervous system stimulants

1. Lisdexamfetamine (Vyvanse)
Psychostimulant used in the attention deficit disorder with hyperactivity in adults and children.

Thrombosis of the vessels

1. Eculizumab
Eculizumab restores the regulation of complement activity in the blood and prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), and prevents excessive activation of the terminal complement complex in patients with atypical hemolytic uremic syndrome (AHUs), where the disease is genetically determined dysregulation of the complement system. On the other hand, deficiency of terminal complement complex is accompanied by increased incidence of infections by encapsulated microorganisms, mainly meningococcal infection. With eculizumab supports the content of the early products of complement activation that is required for opsonization of microorganisms and elimination of immune complexes.

Bones

1. Asfotase alfa (Strensiq)
Asfotase alfa is an enzyme replacement therapy medication to treat a rare disease hypophosphatasia. Hypophosphatasia genetic, chronic and progressive ultra-rare metabolic disease characterized by the mineralization of bones. In this disease the patients are the breakage and deformation of the bones, muscle weakness, convulsions, respiratory failure and not excluded cases of premature death.

Metabolism

1. Sebelipase alfa ((Kanuma)
Sebelius Alfa — recombinant form of the enzyme lysosomal acid lipase. The disease is the accumulation of cholesterol esters (Fig. cholesteryl ester storage disease) or a disease Wolman (eng. Wolman disease) is one of the genetic diseases caused by deficiency of lysosomal acidic lipase. The prevalence of Wolman disease in the world is not more than 1:700 000. The disease is characterized by slow progression, occurs without lesions of the Central nervous system. The age of onset of the disease is from 2 to 23 years. The main symptom is hepatomegaly leading to liver fibrosis. Splenomegaly, liver dysfunction, varicose veins of the esophagus have only some patients. Some patients recurrent abdominal pain, disorders of blood clotting, manifested nasal or gastrointestinal bleeding.

Antifungal

1. Caspofungin (Caspofungin Accord)
Antifungal medication for systemic use. Caspofungin inhibits the synthesis of b-(1,3)-D-glucan is an essential component of the cell wall of many rifamate and yeast. In vitro, caspofungin is active against various pathogenic fungi of the genus Aspergillus and Candida. Caspofungin has excellent activity in the prevention and treatment of pulmonary aspergillosis that identified in research on models of lethal pulmonary infections in vivo.

Anti-inflammatory, anti-allergic

1. Dexamethasone
Лекарственное средство, синтетический глюкокортикостероид, обладающий противовоспалительным и иммунодепрессивным действием наряду со способностью проникать в ЦНС. Благодаря этим свойствам может использоваться при лечении пациентов с отёком мозга и воспалительными заболеваниями глаз (в том числе в сочетании с тобрамицином). Оказывает противовоспалительное, противоаллергическое, десенсибилизирующее, иммунодепрессивное, противошоковое и антитоксическое действие, повышает чувствительность бета-адренорецепторов к эндогенным катехоламинам.
Для применения в офтальмологической практике:
purulent conjunctivitis and allergic, keratitis, keratoconjunctivitis without damaging the epithelium, iritis, iridocyclitis, blepharoconjunctivitis, blepharitis, episcleritis, scleritis, the inflammatory process after eye injuries and surgeries, sympathetic ophthalmia.
For admission into:
Addison's disease-Biermer;
acute and subacute thyroiditis, hypothyroidism, progressive ophthalmopathy associated with thyrotoxicosis;
bronchial asthma;
rheumatoid arthritis in the acute phase;
UC;
diseases of the connective tissue;
autoimmune hemolytic anemia, thrombocytopenia, aplasia and hypoplasia of hematopoiesis, agranulocytosis, serum sickness;
acute erythroderma, pemphigus (normal), acute eczema (early treatment);
malignant tumors (as an antiemetic in cytostatic treatment);
congenital adrenogenital syndrome;
cerebral edema (usually after preliminary parenteral use of corticosteroids, multiple myeloma, prophylaxis after bone marrow transplantation.

Hepatitis, antiviral

1. Sofocbuvir

Alzheimer's Disease

1. Solanezumab

Therapy of osteoarthritis

1. Tanezumab (
blog

BioTechSynthesis
Our projects

BioTechSynthesis
"Only together we can improve people's health and make their lives happier."


Mak Boox
 
book
CARDIOM
Diagnosis of heart mobile devices
book
ARIA
System artificial intelligence assistant
book
IOCC
International outpatient clinical center
book
ONCOM
Diagnosis of cancer
book
TUMBALA
The latest technology, patents, development
blog
 
Contacts

Only together
we can improve people's
health and make their lives happier.

 
1270 Tiegen Dr,
San Francisco
Calif. 94541
LOCATE ON MAP
+1 234 5678 901
+1 234 5678 920
F: +1 245 789865
MORE NUMBERS
hello@1.com
sales@1.com
careers@1.com
OR USE OUR FORM BELOW
S
 
 
 
blog

BioTechSynthesis

BioTechSynthesis engaged in the development, creation and registration of medicines biosimilars and generics.
Biopharmaceutical company is BioTechSynthesis innovative medicines for medical care in the treatment of socially significant diseases.
blog
blog

Health

Health is the most valuable thing a man can have, and address health issues in the modern, constantly changing world is becoming a priority. That's why BioTechSynthesis directs all its efforts to develop and improve the system of medical care, improve the health of millions of people, ensuring their safe, effective innovative medicines.

Care

Concern for patient safety is a priority for BioTechSynthesis and, as at the stage of drug development, and at the stage when the drug is already licensed and widely used in medical practice.
"Only together we can improve people's health and make their lives happier."
 
2012
green icon
IN THE WORLD
MEDPORTAL
In 2012, of cancer in the world died of 8.2 million, and 14.1 million people were diagnosed with similar diseases.
2013
green icon
IN THE WORLD
MEDPORTAL
In 2013, the number of people in the world living with AIDS were reported at 33.2-37.2 million people.
2015
green icon
IN THE WORLD
MEDPORTAL
Worldwide 150-185 million people have hepatitis C.(IMAK, Initiative for Medicines, Access and Knowledge).
2015
green icon
IN THE WORLD
MEDPORTAL
Worldwide, more than 387 million people are living with diagnosed diabetes. (IFD, the international Federation of diabetes).
 
2012
green icon
HUNGARY
MEDPORTAL
Hungary is the country with the highest mortality rate from cancer. Here die of cancer from 313 per 100,000 inhabitants (per year).
2013
green icon
RUSSIA
MEDPORTAL
Stomach cancer has elected his domicile in Japan and Russia.
2013
green icon
Mozambique
MEDPORTAL
In Mozambique, the incidence of liver cancer was 113 cases per 100 000 population, which is 50 times more than in France.
2014
green icon
IN THE WORLD
MEDPORTAL
Estimated global mortality from cancer in 2030 will increase by 45% compared to 2007 (from 7.9 million to 11.5 million deaths) , partly due to population growth and aging of the world population.
 
2015
green icon
RUSSIA
MEDPORTAL
Only Russian citizens infected with AIDS on 01.11.2015 amounted to 986 657 people.
2015
green icon
RUSSIA
MEDPORTAL
Died just 205 538 AIDS, including 20 612 in 2015 (by 16.6% more than the same period in 2014).
2015
green icon
RUSSIA
MEDPORTAL
For 10 months of 2015 revealed 73 777 new cases of AIDS infection among citizens of the Russian Federation, which is 12% higher than the same period in 2014.
blog

BioTechSynthesis

By investing in research and creating optimal conditions for innovation, we are able to make discoveries and create products that meet the immediate needs of patients. Our portfolio of innovative medicines and a large expertise in the key areas of health, as well as a diverse range of promising products allow us to achieve the unique patient outcomes.
blog
 
blog

BioTechSynthesis

Innovation is a cornerstone of the BioTechSynthesis’s business. We are focused on developing medicines that provide pronounced clinical effect which bring tangible benefits to the patient - particularly in those areas where it has the greatest need, for example, in the treatment of hepatitis C, AIDS, neurology, immunology, oncology ....
 

BioTechSynthesis

Looking for potential new therapy for the patients we are watching promising discoveries both within the BioTechSynthsis company and beyond. We practice partnership and cooperation with other companies in the industry, as well as with universities, non-governmental organizations and other groups in finding solutions for patients around the world - knowing that together we can achieve more than alone.
blog
 
blog

BioTechSynthesis

BioTechSynthesis aspires to become a strategic partner of the state and society. Our activities and plans meet many priorities of the state policy in the field of public health, in particular in areas such as increased life expectancy, improved health, prevention of socially significant diseases.
 
Home __ news __ STATISTICS

STATISTICS

/February 09, 2016/ BioTechSynthesis

Oncology

IN THE WORLD:

In 2012, of cancer IN THE WORLD died of 8.2 million, and 14.1 million people were diagnosed with similar diseases. According to forecasts, in 2025 as a result of population ageing cancer annually will be diagnosed 19.3 million people (data of the International Agency for research on cancer IARC).
According to the data, GLOBOCAN 2012, IARC (International Agency for Research on Cancer) RUSSIA in 2012, won 5th place IN THE WORLD in the number of deaths of cancer patients. The number of cases per year were: China – 2205,9 thousand, India – 682,8 thousand, USA – 617,2 thousand, Japan – and RUSSIA 378,6 thousand 295,3 thousand people. The incidence, adjusted for standardized age structure of the population, ASR(W) per 100 000 people in these five countries were: RUSSIA 122,5; China to 122.2; United States – 105,8; Japan – 93.8 and India is 64.5. According cumulative risk (percentage of neonates who will die or will develop cancer before reaching 75 years of age): RUSSIA – 13,69%; China – 11,48%; USA – 11,21%; Japan 9,29% and India – 7,12%.

In Russia:

According to information from the IARC, at the end of 2013 registered with cancer institutions in Russia consisted of more than 3.1 million patients, and that 2% of the population of Russia (data, FSI msroi n. a. P. A. Gertsen). In 2013 in Russia was found 535 887 new cases of malignant neoplasms (54,2% in women, 45.8 per cent of men), which is 15.0% more than in 2003 (455 375). Every minute is one orcadians. Over the past 10 years, the number of cancer patients in the country increased by 25.5%. In 10 years if the situation does not change – there will be more patients by 15-20%.
In Russia more than 300 thousand die each year from malignant neoplasms, i.e. 1000 people every day. With every third patient dies within the first 12 months after diagnosis "cancer" (data of the Association of oncologists of Russia).
Such a gloomy picture due to the fact that more than 40% of patients with cancer diagnosed at stage 3-4. Hence, there is a high percentage of disability. So, in Russia, to cancer disease every year are recognized as disabled of about 190 thousand people.

AIDS

In Russia:

Вthis Russian citizens infected with AIDS on 01.11.2015 amounted to 986 657 people.
Died just 205 538 AIDS, including 20 612 in 2015 (by 16.6% more than the same period in 2014).
Was under medical supervision in 2015 602 837 RUSSIAн infected with AIDS, of whom were receiving antiretroviral therapy 220 366 patients.
For 10 months of 2015 revealed 73 777 new cases of AIDS infection among citizens of the Russian Federation, which is 12% higher than the same period in 2014.
The incidence rate in 2015 was 50.4 per 100 thousand population.
The prevalence of AIDS infection of 1 November 2015 was $ 534,0 on 100 thousand population Russia. the
By 1 November 2015 in Russia there were more than 364 thousand AIDS-positive women who were infected mainly through sexual contact with men.
In Russia in 2015. the epidemic situation on AIDS-infection continued to worsen. the
Remained high incidence of AIDS infection has increased the total number of patients and the number of deaths of AIDS-positive people, intensified the exit of epidemic from vulnerable groups to the General population. (Federal scientific and methodological center for prevention and control of AIDS, Central research Institute of epidemiology of Rospotrebnadzor).

IN THE WORLD:

In 2013, the number of people IN THE WORLD living with AIDS were reported at 33.2-37.2 million people.
Since the beginning of the epidemic, AIDS has infected approximately 71-87 million people and 35-43 million people died from diseases associated with AIDS.
Worldwide the number of people newly infected with AIDS in 2013, was 1.9-2.4 million, less than in 2001, when this number amounted to 3.3-3.6 million..
Globally, the number of children newly infected with AIDS in 2013, amounted to 210 000-280 000, less than in 2001 when the number was 530 000-640 000.
In 2013, worldwide from diseases associated with AIDS, died of 1.4-1.7 million people – for comparison in 2005 this number amounted to 2.2-2.6 million people.
In 2013, around 12.9 million people living with AIDS had access to antiretroviral therapy. This accounts for 35-39% of all people living with AIDS.
Growth in AIDS-infected in 2014 to 53 times compared to 2002
In the most affected countries AIDS has reduced life expectancy by more than 20 years, slowed economic growth and exacerbated the plight of households. Only in Africa South of the Sahara more than 12 million children under the age of 18 had been orphaned by the epidemic. the
AIDS has dramatically skewed the natural age distribution of the population in many African countries South of the Sahara, which can be detrimental from the point of view of transmission of knowledge and values from one generation to the next. the
In Asia, AIDS has caused the strongest decline in productivity than any other disease (Commission on AIDS in Asia, 2008). the
According to the development Programme of the United Nations development programme (UNDP), AIDS has become a cause of “the single greatest reversal in human development” in modern history (UNDP, 2005).

Hepatitis C

In 2015, in five countries: China, Ukraine, RUSSIA, Argentina, Brazil, about 40 million people are living with hepatitis C. In India have more than 12 million people.
Worldwide 150-185 million people have hepatitis C.(IMAK, Initiative for Medicines, Access and Knowledge).

Diabetes

Worldwide, more than 387 million people are living with diagnosed diabetes. (MFD, the international Federation of diabetes).
Home __ News__ Biosimilars and Generics.

Biosimilars and Generics

/February 09, 2016/ BioTechSynthesis


The company BioTechSynthesis biosimilars and the original drugs according to three criteria - pharmaceutical (compliance with chemical formulas), biological (similar to the behavior in the body – absorption, destruction) and therapeutic (efficacy and safety) equivalence (According to drugs).
According to world practice, the cost of developing bioanalogous is from 100 to 250 million dollars (for generics is about 5 million dollars) and takes 3-5 years. Technology company BioTechSynthesis reduce significantly the cost and time of development of biosimilars.
Biosimilars may enhance competition, as the value of the biosimilars market is 10-40% below the price of the original drug. The reduction is due to the fact that the followers optimize costs and not repeat the path traversed by the pioneer (after all, any path including stub areas).
Today, specialists BioTechSynthesis developed a large number of biosimilars and generics.
Biosimilars - an exact copy of the original.
Home __ News __Kaletra

Kaletra

/February 11, 2016/ BioTechSynthesis


Antiviral agent, a peptide inhibitor of AIDS-1 and AIDS-2 proteases. Enzymatic cleavage of the protease prevents the activation of the protein precursor and leads to the synthesis of immature AIDS particles unable to initiate further development of the infection. Proteolysis of polypeptides of AIDS life cycle stops its replication. Binds C2-symmetric part of the active area of AIDS protease, has a high selective affinity for and has a weak inhibitory effect on the protease of human rights. Increases the number of CD4 cells in the blood and reduces the concentration of viral RNA. Leads to an increase in the total number of white blood cells, lymphocytes and platelets.
Home __ News __Alogliptin

Alogliptin

/February 09, 2016/ BioTechSynthesis


Alogliptin is a highly selective inhibitor of DPP-4. In clinical studies of up to two years application alogliptin, both in monotherapy and in combination with other sugar-reducing drugs resulted in significant improvement in glycaemic control in patients with type 2 diabetes, including old age. Application alogliptin accompanied by a low risk of hypoglycaemia and lack of weight gain. In patients at very high cardiovascular risk the use of alogliptin-on not associated with an increased risk of cardiovascular events.
Home __ News __ Propanolol

Propanolol

/February 19, 2016/ BioTechSynthesis


Arterial hypertension; stable angina, unstable angina; sinus tachycardia (including in hyperthyroidism), supraventricular tachycardia, tachysystolic form of atrial fibrillation, supraventricular and ventricular premature beats, essential tremor, migraine prophylaxis, alcohol withdrawal (agitation, and tremor), anxiety, pheochromocytoma (adjuvant treatment), diffuse toxic goiter and thyrotoxic crisis (as subsidiary means, including intolerance to thyreostatics drugs), sympathoadrenal crises on the background of diencephalic syndrome.
Home __ News __Naphazoline

Naphazoline

/February 22, 2016/ BioTechSynthesis


Stimulates alpha1 - and ALPHA2-adrenergic receptors, causes vasoconstriction (primarily affects the vessels with the highest density of alpha-adrenoceptor — vessels of the mucous membranes and kidneys), the pupil narrows, has anti-inflammatory (anti-edema) properties. Vasoconstrictive effect for local application to the mucous membrane of the nose and eyes occurs within minutes and lasts for hours. In rhinitis nasal breathing easier, reducing blood flow to the venous sinuses. Systemic effect manifested by increased arterial pressure
Home __ News __Rifaximin

Rifaximin

/February 24, 2016/ BioTechSynthesis
The broad-spectrum antibiotic, is a semisynthetic derivative of rifamycin SV. Inhibits DNA-dependent RNA polymerase of bacterial cells and causes their death. Broad antibacterial spectrum of rifaximin suppresses pathogenic intestinal bacterial flora, which causes a number of pathological conditions. Rifaximin reduces the formation by bacteria of ammonia and other toxic compounds, which in the case of severe liver disease, accompanied by violation of the detoxification process, are involved in the pathogenesis and symptomatology of hepatic encephalopathy. Reduces the increased proliferation of bacteria in the syndrome of excessive growth of microorganisms in the intestines. In the diverticula of the colon reduces the number of bacteria that can participate in inflammation around the diverticular SAC, and may play a key role in the development of symptoms and complications of diverticular disease.
Home __ News __Filgrastim

Filgrastim

/February 26, 2016/ BioTechSynthesis


To reduce the duration of neutropenia and the frequency of febrile neutropenia in patients receiving chemotherapy cytotoxic drugs for malignant diseases (except chronic myeloid leukemia and myelodysplastic syndrome), also reducing the duration of neutropenia and its clinical in posledstviyami in patients receiving therapy with myeloablative in posledstviyami bone marrow transplantation.
For mobilization of autologous progenitor cells hematopoiesis in the peripheral blood, including in consequence of myelosuppressive therapy to accelerate recovery of hematopoiesis by introduction of these cells in consequence of mielosupression or myeloablative.
Long-term therapy to increase the number of neutrophils and reduce the frequency and duration of infectious complications in children and adults with severe congenital, malignant or recurrent neutropenia (absolute neutrophil count <500/µl) and severe or recurrent infections in history.